This new LPPS technology materially reduces solvent demand and the need for excess reagents compared to standard solid-state peptide synthesis processes. The LPPS technology supports peptides up to 12 residues long, with larger peptides assembled in liquid-phase using a convergent fragment coupling reaction. Processes developed with this LPPS technology can be scaled in the same way as traditional small molecules.

In addition to this technology, Cambrex developed a crystallization screening platform to discover crystalline forms of peptides and proteins. Crystallization can deliver improved product quality and stability and reduce the need for time-consuming preparative chromatography and lyophilization.

“Over the past several years, we have made significant investments in the research and development of complex synthetics, specifically to reduce the economic and environmental impacts of manufacturing peptides and oligonucleotides,” said Matt Bio, Chief Scientific Officer, of the contract development and manufacturing organization (CDMO). “Our new LPPS technology provides a significantly more cost-efficient and environmentally sustainable solution when compared to traditional solid-phase peptide synthesis, substantially reducing solvent usage and allowing the substitution of sustainable solvents.”

“With the clinical and commercial successes of peptide-based therapies, it’s imperative that we provide industry-leading solutions to develop and scale peptide candidates,” said Thomas Loewald, CEO at Cambrex.